Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present BioXcel Therapeutics, Inc. (NASDAQ: BTAI).

Full DD Report for BTAI

You must become a subscriber to view this report.


Recent News from (NASDAQ: BTAI)

BioXcel Therapeutics to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
NEW HAVEN, Conn., Dec. 03, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immun...
Source: GlobeNewswire
Date: December, 03 2018 06:00
BioXcel Therapeutics Announces FDA Acceptance of IND for Lead Immuno-oncology Candidate, BXCL701, in Treatment Emergent Neuroendocrine Prostate Cancer
First-in-human Phase 1b / 2 combination trial of BXCL701 and pembrolizumab (Keytruda®) expected to initiate in 4Q 2018 Efficacy study with objective response rate endpoint to enroll up to 40 patients at multiple clinical sites NEW HAVEN, Conn., Nov. 05, 2018 (GLOBE NEWSWIR...
Source: GlobeNewswire
Date: November, 05 2018 04:00
BioXcel Therapeutics to Host Third Quarter 2018 Financial Results and Business Update Conference Call
Conference call scheduled for November 09, 2018 at 8:00 AM ET NEW HAVEN, Conn., Nov. 02, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to...
Source: GlobeNewswire
Date: November, 02 2018 06:00
BioXcel Therapeutics Announces Presentation on Functional Immunological Memory Formation Across Diverse Tumor Types at the SITC 2018 Annual Meeting
Data underscores the potential of triple combination of BXCL701, NKTR-214 and an anti-PD1 agent as an anti-cancer therapy  NEW HAVEN, Conn., Oct. 31, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical develo...
Source: GlobeNewswire
Date: October, 31 2018 04:00
BioXcel Therapeutics Provides Update on the Clinical Advancement of BXCL501 for the Acute Treatment of Agitation
On track to initiate BXCL501 first-in-human pharmacokinetic (bioavailability) and safety study Data readout expected first half 2019 NEW HAVEN, Conn., Oct. 30, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutic...
Source: GlobeNewswire
Date: October, 30 2018 04:00
BioXcel Therapeutics Appoints Dr. David C. Hanley as Vice President and Head of Global Pharmaceutical Development and Operations
BRANFORD, Conn., Sept. 04, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology,...
Source: GlobeNewswire
Date: September, 04 2018 08:00
BioXcel Therapeutics to Present at the 20th Annual HC Wainwright Global Investment Conference
NEW HAVEN, Conn., Aug. 28, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immun...
Source: GlobeNewswire
Date: August, 28 2018 08:00
BioXcel Therapeutics Establishes Immuno-Oncology Clinical Advisory Board to Advance BXCL701 Development
NEW HAVEN, Conn., Aug. 22, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immun...
Source: GlobeNewswire
Date: August, 22 2018 08:00
BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q2 2018 Results - Earnings Call Transcript
BioXcel Therapeutics, Inc. (BTAI) Q2 2018 Earnings Conference Call August 08, 2018, 16:30 ET Executives Lee Roth - SVP, The Ruth Group Vimal Mehta - Founder, CEO, President, Secretary & Director Richard Steinhart - CFO Frank Yocca - Chief Scientific Officer Vincent O'Neil...
Source: SeekingAlpha
Date: August, 12 2018 02:13
BioXcel Therapeutics beats by $0.13
BioXcel Therapeutics (NASDAQ: BTAI ): Q2 EPS of -$0.19 beats by $0.13 . More news on: BioXcel Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 08 2018 16:45

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-089.169.319.499.0811,727
2018-05-179.8910.5410.698.9217,841

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-182,2877,15931.9458Cover
2018-12-1720111,6501.7253Cover
2018-12-1479144,1411.7920Cover
2018-12-131811,45212.4656Cover
2018-12-127,17916,93342.3965Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BTAI.


About BioXcel Therapeutics, Inc. (NASDAQ: BTAI)

Logo for BioXcel Therapeutics, Inc. (NASDAQ: BTAI)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: BTAI)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 17 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 14 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 14 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 26 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: April, 10 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 13 2018
      Prospectus filed under Rule 424(b)(4)
      Filing Type: 424B4Filing Source: edgar
      Filing Date: March, 09 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: March, 08 2018
      Notice from the SEC of registration effectiveness
      Filing Type: EFFECTFiling Source: edgar
      Filing Date: March, 07 2018
      Amendment to general form for registration of securities under the Securities Act of 1933
      Filing Type: S-1/AFiling Source: edgar
      Filing Date: March, 05 2018

       

       


      Daily Technical Chart for (NASDAQ: BTAI)

      Daily Technical Chart for (NASDAQ: BTAI)


      Stay tuned for daily updates and more on (NASDAQ: BTAI)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: BTAI)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BTAI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of BTAI and does not buy, sell, or trade any shares of BTAI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/